11/19
08:41 am
lyel
LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment [Yahoo! Finance]
Medium
Report
LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment [Yahoo! Finance]
11/14
01:37 pm
lyel
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Neutral
Report
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
11/14
08:22 am
lyel
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors [Yahoo! Finance]
Low
Report
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors [Yahoo! Finance]
11/12
08:33 am
lyel
Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
Low
Report
Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
11/7
04:05 pm
lyel
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
Low
Report
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
11/5
09:30 am
lyel
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
Medium
Report
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
10/31
04:00 pm
lyel
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
High
Report
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
10/30
07:27 am
lyel
Lyell Immunopharma, Inc. (NASDAQ: LYEL) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $6.00.
Medium
Report
Lyell Immunopharma, Inc. (NASDAQ: LYEL) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $6.00.
10/28
08:25 am
lyel
Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
Medium
Report
Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
10/25
09:26 am
lyel
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth [Seeking Alpha]
High
Report
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth [Seeking Alpha]
10/24
04:07 pm
lyel
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies [Yahoo! Finance]
High
Report
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies [Yahoo! Finance]
10/24
04:00 pm
lyel
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
High
Report
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
10/4
09:00 am
lyel
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
9/24
04:05 pm
lyel
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
Medium
Report
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
9/5
09:27 pm
lyel
Iovance Therapeutics: Historic Product, Tough Commercial Outlook [Seeking Alpha]
Medium
Report
Iovance Therapeutics: Historic Product, Tough Commercial Outlook [Seeking Alpha]
8/28
04:05 pm
lyel
Lyell Immunopharma Announces Participation in September Investor Conferences
Low
Report
Lyell Immunopharma Announces Participation in September Investor Conferences
8/24
10:27 am
lyel
Recent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past year [Yahoo! Finance]
Medium
Report
Recent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past year [Yahoo! Finance]